Literature DB >> 15922944

Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies.

Michael F Good1.   

Abstract

A genetically modified malaria sporozoite might breathe new life into the traditional approach to vaccine development, that of using whole organisms. Mueller and colleagues recently knocked out a gene, UIS3, from the rodent parasite, Plasmodium berghei, and demonstrated that the sporozoite forms could not develop beyond the stage of the life cycle in the liver (thus not giving rise to clinical disease, which is associated with blood infection) but could induce protection against subsequent challenge with genetically intact sporozoites. UIS3(-) sporozoites or irradiated sporozoites might find success where subunit approaches are struggling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15922944     DOI: 10.1016/j.it.2005.04.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  9 in total

1.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

2.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

Review 3.  Genetically engineered, attenuated whole-cell vaccine approaches for malaria.

Authors:  Ashley M Vaughan; Ruobing Wang; Stefan H I Kappe
Journal:  Hum Vaccin       Date:  2010-01-29

4.  Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells.

Authors:  Ann-Kristin Mueller; Martina Deckert; Kirsten Heiss; Kristin Goetz; Kai Matuschewski; Dirk Schlüter
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 5.  Acquired immunity to malaria.

Authors:  Denise L Doolan; Carlota Dobaño; J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

6.  Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection.

Authors:  Mehdi Labaied; Anke Harupa; Ronald F Dumpit; Isabelle Coppens; Sebastian A Mikolajczak; Stefan H I Kappe
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

7.  Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.

Authors:  Susanne Tartz; Jana Kamanova; Marcela Simsova; Peter Sebo; Stefanie Bolte; Volker Heussler; Bernhard Fleischer; Thomas Jacobs
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

8.  Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.

Authors:  Arlene E Dent; Elke S Bergmann-Leitner; Danny W Wilson; Daniel J Tisch; Rhonda Kimmel; John Vulule; Peter Odada Sumba; James G Beeson; Evelina Angov; Ann M Moormann; James W Kazura
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

9.  Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and infectivity.

Authors:  Edwin Lasonder; Chris J Janse; Geert-Jan van Gemert; Gunnar R Mair; Adriaan M W Vermunt; Bruno G Douradinha; Vera van Noort; Martijn A Huynen; Adrian J F Luty; Hans Kroeze; Shahid M Khan; Robert W Sauerwein; Andrew P Waters; Matthias Mann; Hendrik G Stunnenberg
Journal:  PLoS Pathog       Date:  2008-10-31       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.